Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0027947 (neutropenia)
 17,527 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The authors have studied the efficacy and safety of recombinant human granulocyte colony-stimulating factor (rhG-CSF, Granulocyte Injection) on leucopenia and neutropenia induced by chemotherapy with regimen CE (Carboplatin and Etoposide) in lung cancer patients in a randomized, matched and cross-over clinical trial. The total enrolled patients were twenty-two. They were randomized into A and B groups (11 patients in each group). Each patient received two cycles treatment. In group A chemotherapy and rhG-CSF were used in the first cycle and chemotherapy alone was used in the second cycle, while in group B chemotherapy alone was used in the first cycle and chemotherapy and rhG-CSF were used in the second cycle. The results showed that rhG-CSF significantly increased the number of white blood cell (WBC) and absolute neutrophil count (ANC) at the nadir, decreased incidence of leucopenia and neutropenia, and reduced the number of days with WBC < 4.0 x 10(9)/L, ANC < 2.5 x 10(9)/L as well as the number of days with WBC > 4.0 x 10(9)/L and ANC > 2.5 x 10(9)/L. rhG-CSF ensures the completion of chemotherapy and its side-effects were slight.
Zhonghua Nei Ke Za Zhi 1994 Nov
PMID:[Clinical study of recombinant human granulocyte colony-stimulating factor (RHG-CSF) on leucopenia induced by chemotherapy with CE regimen on lung cancer patients]. 754 25

In order to approach antibacterial activity in vitro and the efficacy of Sulperazon (SPZ) (sulbactam/cefoperazone), the sensitivity tests of 1,372 strains from clinical isolated bacteria to 17 antibiotics including SPZ were determined. The Gram negative bacteria occupied 1,035 strains (75.4) and Gram positive 337 strains (24.6%). 50 episodes of infections of major respiratory system in 43 patients were treated by SPZ. 58% of bacterial infections occurred in hematologic malignant diseases and solid tumors patients. 24% of 50 episodes were in neutropenia status. The positive rate of bac-terial cluteres was 56% in the series. 1.0-2.0 g SPZ was administered twice a day for 5-18 days, 56% of them was more than seven days (28/50 episodes). The results of susceptibility tests showed that sensitive rates were most high and the nesistant rates of SPZ were lower than these of to common Gram negative and Gram positive bacteria in third-generation cephalosporins. The efficacy rate of SPZ in clinical use was 84% (42/50 episodes), bacterial clearance rate was 89% (25/28 episodes). Three cases (6%) had temporary elevation and other adverse reactions of SPZ were not seen.
Zhonghua Nei Ke Za Zhi 1997 Jun
PMID:[Antibacterial activity in vitro and clinical use of sulperazon]. 1037 2